NEW YORK BioAffinity Technologies Inc, ticker BIAF, outlined its growing commercial footprint and rising diagnostic volume during an exclusive sit down interview with Marathon Money. The conversation featured Maria Zannes, the company’s president and chief executive officer, who provided new details about revenue expansion, clinical adoption, and the company’s early detection technology.

The full video interview is available for viewers who want the complete discussion and deeper context behind the company’s progress.

Zannes said the company’s CyPath Lung test, created for the early detection of lung cancer, is already in use across multiple clinics and small hospital systems in Texas. She said the company is expanding into additional states as physicians continue adopting the technology.

BioAffinity reported revenue of 2.3 million in 2023 and 9.36 million in 2024. The company has generated 1.8 million so far this year. Zannes said the growth reflects stronger real world use of the diagnostic test and increasing recognition among clinicians.

The company also reported a 111 percent increase in test volume in 2025. Zannes said the rise shows that more physicians are integrating CyPath Lung into their diagnostic workflow for patients who require early evaluation.

CyPath Lung uses a sputum based process that helps doctors identify signs of lung cancer earlier while reducing unnecessary invasive procedures. Zannes said the company is preparing additional products built on the same scientific platform as part of a broader diagnostic pipeline.

She also said the company is focused on reducing debt and managing operational costs as it scales into new markets.

ANALYST NOTES

Analysts reviewing the interview described bioAffinity Technologies as a company moving from an early development phase into commercial growth. The jump in annual revenue and ongoing adoption in clinical settings were cited as indicators of increasing stability.

The company’s low share float, under 30 million shares, was noted as a factor that may heighten volatility if investor awareness increases. Analysts said the company’s expansion beyond Texas could position it for stronger multi state revenue growth.

Analysts said the company’s long term performance will depend on continued physician adoption, the successful launch of new diagnostic products, and consistent financial management. Early detection of lung cancer remains a significant medical need, and analysts said the company is well positioned within that market.

COMMUNITY OUTLOOK

Members of the Marathon Money community expressed interest in the company following the release of the interview. Many viewers focused on the company’s revenue growth and the steady rise in test volume. Others highlighted the importance of already having a commercial product in the market, which separates bioAffinity from other early stage biotech companies.

Community feedback centered on key themes.
The company already has paying clinical customers.
Revenue is rising as adoption spreads.
Test volume shows meaningful growth.
Expansion into new states could widen the company’s footprint.
Additional diagnostic products could support long term value.

Based on the interview, many in the community believe bioAffinity Technologies has the potential to expand further if current adoption trends continue. Viewers of the program said they will be watching closely as the company advances its growth strategy.